<H1>Chapter DOI: 10.1007/978-1-60327-829-4_2<br/>Cited-By Count: 0</H1><table border="1" width="30%"><tr><td>Total References</td><td>102</td></tr><tr><td>Springer references</td><td>1</td></tr><tr><td>Non Springer references</td><td>101</td></tr><tr><td>BibStructured Count</td><td width="10%">102</td></tr><tr><td>BibUnstructured Count</td><td width="10%">0</td></tr><tr><td>DOI already available in SpringerLink</td><td>74</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>4</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>4</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>4</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1_2</td><td>BibArticle</td><td>Schally AV, Arimura A, Kastin AJ. Hypothalamic FSH and LH-regulating hormone: Structure, physiology and clinical studies. Fertil Steril 1971;22:703&#8211;721.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR2_2</td><td>BibArticle</td><td>Schally AV. Aspects of hypothalamic regulation of the pituitary gland. Science 1978;202:18&#8211;28.</td><td><a href=http://dx.doi.org/10.1126/science.99816>10.1126/science.99816</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3_2</td><td>BibArticle</td><td>Clayton RN, Catt KJ. GnRH receptors: Characterization, physiologic regulation and relationship to reproductive functions. Endocr Rev 1981;2(2):186&#8211;209.</td><td><a href=http://dx.doi.org/10.1210/edrv-2-2-186>10.1210/edrv-2-2-186</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4_2</td><td>BibArticle</td><td>Conn PM, Huckle WR, Anders WV, McArdle CA. The molecular mechanism of action of gonadotropin releasing hormone (GnRH) in the pituitary. Recent Prog Horm Res 1987;43:29&#8211;68.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/B978-0-12-571143-2.50007-1>10.1016/B978-0-12-571143-2.50007-1</a></td><td><b>CrossRef-Meta</b></td>
<td>Year, Author_FamilyName_2, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR5_2</td><td>BibArticle</td><td>Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev 2004;25;235&#8211;275.</td><td><a href=http://dx.doi.org/10.1210/er.2003-0002>10.1210/er.2003-0002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6_2</td><td>BibChapter</td><td>Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In: Holland JF, Frei E, Bast RC, Kufe DE, Pollock RE, Weichselbaum RR, Hait WN, Hong WK, eds. Cancer medicine. 7th ed. Hamilton, ON: BC Dekker, 2006:802&#8211;816.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR7_2</td><td>BibArticle</td><td>Schally AV, Comaru-Schally AV, Nagy A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22:248&#8211;291.</td><td><a href=http://dx.doi.org/10.1006/frne.2001.0217>10.1006/frne.2001.0217</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8_2</td><td>BibArticle</td><td>Reissmann T, Schally AV, Bouchard P, Riethmuller H, Engel J. The LHRH antagonist cetrorelix: A review. Hum Reprod Update 2000;6:322&#8211;331.</td><td><a href=http://dx.doi.org/10.1093/humupd/6.4.322>10.1093/humupd/6.4.322</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9_2</td><td>BibArticle</td><td>Griesinger G, Felberbaum R, Diedrich K. GnRH-antagonists in reproductive medicine. Arch Gynecol Obstet 2005;273:71&#8211;78.</td><td><a href=http://dx.doi.org/10.1007/s00404-005-0021-2>10.1007/s00404-005-0021-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10_2</td><td>BibArticle</td><td>Kov&#225;cs M, Schally AV. Comparison of mechanism of action of LHRH antagonist cetrorelix and LHRH agonist triptorelin on the gne expression of pituitary LHRH receptors in rats. Proc Natl Acad Sci USA 2001;987:12197&#8211;12202.</td><td><a href=http://dx.doi.org/10.1073/pnas.211442598>10.1073/pnas.211442598</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11_2</td><td>BibArticle</td><td>Kov&#225;cs M, Schally AV, Csernus B, Rekasi Z. LHRH antagonist cetrorelix downregulates the mRNA expression of pituitary receptors for LHRH by counteracting the stimulatory effect of endogenous LHRH. Proc Natl Aca Sci USA 2001;98:1829&#8211;1834.</td><td><a href=http://dx.doi.org/10.1073/pnas.98.4.1829>10.1073/pnas.98.4.1829</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12_2</td><td>BibArticle</td><td>Horvath JE, Bajo AM, Schally AV, Kov&#225;cs M, Herbert F, Groot K. Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the level of pituitary LHRH receptors and their mRNA expression in rats. Proc Natl Acad Sci U S A 2002;99:15048&#8211;15053.</td><td><a href=http://dx.doi.org/10.1073/pnas.232579499>10.1073/pnas.232579499</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13_2</td><td>BibArticle</td><td>Schally AV. Luteinizing hormone releasing-hormone analogues: Their impact on the control of tumorigenesis. Peptides 1999;20:1247&#8211;1262.</td><td><a href=http://dx.doi.org/10.1016/S0196-9781(99)00130-8>10.1016/S0196-9781(99)00130-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14_2</td><td>BibArticle</td><td>Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de Maturana R, Millar RP. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004;64:7533&#8211;7544.</td><td><a href=http://dx.doi.org/10.1158/0008-5472.CAN-04-1360>10.1158/0008-5472.CAN-04-1360</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15_2</td><td>BibArticle</td><td>Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol 1999;141:1&#8211;14.</td><td><a href=http://dx.doi.org/10.1530/eje.0.1410001>10.1530/eje.0.1410001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16_2</td><td>BibArticle</td><td>Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003;72:2305&#8211;2320.</td><td><a href=http://dx.doi.org/10.1016/S0024-3205(03)00113-9>10.1016/S0024-3205(03)00113-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17_2</td><td>BibArticle</td><td>Krebs JL, Wang X, Pudavar HE, et al. Regulation of targeted chemotherapy with cytotoxic LHRH analog by epidermal growth factor. Cancer Res 2000;60:4194&#8211;4199.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR18_2</td><td>BibArticle</td><td>Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab 2004;15:300&#8211;310.</td><td><a href=http://dx.doi.org/10.1016/j.tem.2004.07.002>10.1016/j.tem.2004.07.002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19_2</td><td>BibArticle</td><td>Schally AV, Arimura A, Baba Y, et al. Isolation and properties of the FSH- and LH-releasing hormone. Biochem Biophys Res Commun 1971;43:393&#8211;399.</td><td><a href=http://dx.doi.org/10.1016/0006-291X(71)90766-2>10.1016/0006-291X(71)90766-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20_2</td><td>BibArticle</td><td>Matsuo H, Baba Y, Nair RMG, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971;43:1334&#8211;1339.</td><td><a href=http://dx.doi.org/10.1016/S0006-291X(71)80019-0>10.1016/S0006-291X(71)80019-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21_2</td><td>BibArticle</td><td>Schally AV, Arimura A, Kastin A, et al. The gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science 1971;173:1036&#8211;1038.</td><td><a href=http://dx.doi.org/10.1126/science.173.4001.1036>10.1126/science.173.4001.1036</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22_2</td><td>BibArticle</td><td>Kastin AJ, Schally AV, Gual C, Midgley AR Jr, Bowers CY, Gomez-Perez E. Administration of LH-releasing hormone to selected human subjects. Am J Obstet Gynecol 1970;108: 177&#8211;182.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR23_2</td><td>BibArticle</td><td>Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: Rationale and perspective. Endocr Rev 1986;7:44&#8211;66.</td><td><a href=http://dx.doi.org/10.1210/edrv-7-1-44>10.1210/edrv-7-1-44</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24_2</td><td>BibArticle</td><td>Schally AV, Kastin AJ, Coy DH, Edward T. Tyler Prize Oration. LH-releasing hormone and its analogs: recent basic and clinical investigations. Int J Fertil 1976;21:1&#8211;30.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25_2</td><td>BibArticle</td><td>Coy DH, Vilchez-Martinez JA, Coy EJ, Schally AV. Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem 1976;19:423&#8211;425.</td><td><a href=http://dx.doi.org/10.1021/jm00225a018>10.1021/jm00225a018</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26_2</td><td>BibArticle</td><td>Fujino M, Fukuda T, Shinagawa S, et al. Synthetic analogs of luteinizing hormone-releasing hormone (LHRH) substituted in positions 6 and 10. Biochem Biophys Res Commun 1974;57:1248&#8211;1256.</td><td><a href=http://dx.doi.org/10.1016/0006-291X(74)90830-4>10.1016/0006-291X(74)90830-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27_2</td><td>BibArticle</td><td>Dutta AN. Luteinizing hormone-releasing hormone (LHRH) agonists. Drugs Future 1988;13:43&#8211;57.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR28_2</td><td>BibArticle</td><td>Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical in that found in pituitary. Mol Cell Endocrinol 1994;106:145&#8211;149.</td><td><a href=http://dx.doi.org/10.1016/0303-7207(94)90196-1>10.1016/0303-7207(94)90196-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29_2</td><td>BibArticle</td><td>Neill JD. GnRH and GnRH receptor genes in the human genome. Endocrinology 2002;143:737&#8211;743.</td><td><a href=http://dx.doi.org/10.1210/en.143.3.737>10.1210/en.143.3.737</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30_2</td><td>BibArticle</td><td>Schlegel PN. Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J Urol 2006;175:1353&#8211;1358.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)00649-X>10.1016/S0022-5347(05)00649-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31_2</td><td>BibArticle</td><td>Bajusz S, Kov&#225;cs M, Gazdag M, eta al. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci USA 1988;85:1637&#8211;1641.</td><td><a href=http://dx.doi.org/10.1073/pnas.85.5.1637>10.1073/pnas.85.5.1637</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32_2</td><td>BibChapter</td><td>Schally AV, Engel J. Analogs of luteinizing hormone-releasing hormone (LHRH) in cancer. In: Handbook of biologically active peptides. Kastin AJ, ed. Academic Press: New York, 2006:421&#8211;427.</td><td><a href=http://dx.doi.org/10.1016/B978-012369442-3/50063-5>10.1016/B978-012369442-3/50063-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33_2</td><td>BibArticle</td><td>Nelson LR, Fujimoto VY, Jaffe RB, Monroe SE. Suppression of follicular phase pituitary gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil Steril 1995;63:963&#8211;969.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR34_2</td><td>BibArticle</td><td>Molineaux CJ, Sluss PM, Bree MP, Geefter ML, Sullivan LM, Garnick BM. Suppression of plasma gonadotropins by Abarelix: A potent new LHRH antagonist. Mol Urol 1998;2:265&#8211;268.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR35_2</td><td>BibArticle</td><td>Pinski J, Yano T, Szepesh&#225;zi K, Groot K, Schally AV. Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix SB-75. J Androl 1993;14:164&#8211;169.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR36_2</td><td>BibArticle</td><td>Samant MP, Hong DJ, Croston G, Rivier C, Rivier J. Novel analogues of degarelix incorporating hydroxyl-, methoxy- and pegylated-urea moieties at positions 3,5,6 and the N-Terminus. J Med Chem 2006;49:3536&#8211;3543.</td><td><a href=http://dx.doi.org/10.1021/jm060240a>10.1021/jm060240a</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37_2</td><td>BibArticle</td><td>Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold OT. Degarelix: a novel gonadotropin-releasing hormone (GNRH) receptor blocker-results from a 1-yr, multicentre, randomized, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805&#8211;813.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2008.04.065>10.1016/j.eururo.2008.04.065</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37a_2</td><td>BibArticle</td><td>Gittelman M, Pommerville PJ, Persson BE, et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008;180(5):1986&#8211;1992.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR37b_2</td><td>BibArticle</td><td>Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531&#8211;1538.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38_2</td><td>BibArticle</td><td>Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update 2006;12:333&#8211;340.</td><td><a href=http://dx.doi.org/10.1093/humupd/dml001>10.1093/humupd/dml001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39_2</td><td>BibArticle</td><td>Armer RE, Smelt KH. Non-peptidic GnRH receptor antagonists. Curr Med Chem 2004;11:3017&#8211;3026.</td><td><a href=http://dx.doi.org/10.2174/0929867043363983>10.2174/0929867043363983</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40_2</td><td>BibArticle</td><td>Kov&#225;cs M, Kopp&#225;n M, Mez&#337; I, Tepl&#225;n I. Diverse effects of a potent LHRH antagonist on the LH and FSH release. Acta Biol Hung 1994;45:285&#8211;296.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR41_2</td><td>BibArticle</td><td>Bokser L, Srkalovic G, Szepeshazi K, et al. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75). Neuroendocrinology 1991;54:136&#8211;145.</td><td><a href=http://dx.doi.org/10.1159/000125862>10.1159/000125862</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42_2</td><td>BibArticle</td><td>Pinski J, Yano T, Groot K, et al. Comparison of biological effects of a sustained delivery system and nonecapsulated LH-RH antagonist SB-75 in rats. Peptides 1992;13:905&#8211;911.</td><td><a href=http://dx.doi.org/10.1016/0196-9781(92)90048-8>10.1016/0196-9781(92)90048-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43_2</td><td>BibArticle</td><td>Halmos G, Schally AV, Pinski J, et al. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Proc Natl Acad Sci USA 1996;93:2398&#8211;2402.</td><td><a href=http://dx.doi.org/10.1073/pnas.93.6.2398>10.1073/pnas.93.6.2398</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44_2</td><td>BibArticle</td><td>Pinski J, Lamharzi N, Halmos G, et al. Chronic administration of luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology 1996;137:3430&#8211;3436.</td><td><a href=http://dx.doi.org/10.1210/en.137.8.3430>10.1210/en.137.8.3430</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45_2</td><td>BibArticle</td><td>Behre HM, Kliesch S, P&#252;hse G, et al. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteininzing hormone, follicle-stimulating hormone, and testosterone in normal men. J Clin Endocrinol Metab 1997;82:1403&#8211;1408.</td><td><a href=http://dx.doi.org/10.1210/jc.82.5.1403>10.1210/jc.82.5.1403</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46_2</td><td>BibArticle</td><td>Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotropin-releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990;62:96&#8211;99.</td><td><a href=http://dx.doi.org/10.1038/bjc.1990.236>10.1038/bjc.1990.236</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47_2</td><td>BibArticle</td><td>Halmos G, Arenciba JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LH-RH) and LH-RH receptor gene expression in human prostate cancers. J Urology 2000;163:623&#8211;629.</td><td><a href=http://dx.doi.org/10.1016/S0022-5347(05)67947-5>10.1016/S0022-5347(05)67947-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48_2</td><td>BibArticle</td><td>Straub B, M&#252;ller M, Krause H, et al. Increased incidence of LHRH receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Cancer Res 2001;7:2340&#8211;2343.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR49_2</td><td>BibArticle</td><td>Limonta P, Dondi D, Roberta M, et al. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1993;76:797&#8211;800.</td><td><a href=http://dx.doi.org/10.1210/jc.76.3.797>10.1210/jc.76.3.797</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50_2</td><td>BibArticle</td><td>Schally AV, Halmos G, Rekasi Z, Arencibia-Jimenez JM. The actions of luteinizing hormone-releasing hormone agonists, antagonists, and cytotoxic analogues on the luteinizing hormone-releasing hormone receptors on the pituitary and tumors. Infert Reprod Med Clin North Amer 2001;12:17&#8211;44.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR51_2</td><td>BibArticle</td><td>Eidne KA, Flanagan CA, Millar RP. Gonadotropin-releasing hormone binding sites in human breast carcinoma. Science 1985;229:989&#8211;991.</td><td><a href=http://dx.doi.org/10.1126/science.2992093>10.1126/science.2992093</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52_2</td><td>BibArticle</td><td>Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 1985;313:231&#8211;233.</td><td><a href=http://dx.doi.org/10.1038/313231a0>10.1038/313231a0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53_2</td><td>BibArticle</td><td>Fekete M, Wittliff JL, Schally AV. Characteristics and distribution of receptors for [D-Trp<Superscript>6</Superscript>]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal 1989;3:137&#8211;147.</td><td><a href=http://dx.doi.org/10.1002/jcla.1860030302>10.1002/jcla.1860030302</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR54_2</td><td>BibArticle</td><td>Emons G, Schally AV. The use of luteinizing hormone releaseing hormone agonists and antagonists in gynaecological cancers. Reproduction 1994;9:1364&#8211;1379.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR55_2</td><td>BibArticle</td><td>Srkalovic G, Schally AV, Wittliff JL, Day G, Jenison EL. Presence and characteristics of receptors for [D-Trp<Superscript>6</Superscript>]-luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol 1998;12:489&#8211;498.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.3892/ijo.12.3.489>10.3892/ijo.12.3.489</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Year, Author_FamilyName_2, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR56_2</td><td>BibArticle</td><td>Srkalovic G, Wittliff JL, Schally AV. Detection and partial characterization of receptors for [D-Trp6]luteinizing hormone-releasing hormone in human endometrial carcinoma. Cancer Res 1990;50:1841&#8211;1846.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR57_2</td><td>BibArticle</td><td>Engel J B, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007;3:157&#8211;167.</td><td><a href=http://dx.doi.org/10.1038/ncpendmet0399>10.1038/ncpendmet0399</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58_2</td><td>BibArticle</td><td>Emons G, Ortmann O, Schulz KD, et al. Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab 1997;8:355&#8211;362.</td><td><a href=http://dx.doi.org/10.1016/S1043-2760(97)00155-0>10.1016/S1043-2760(97)00155-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59_2</td><td>BibArticle</td><td>Irmer G, Burger C, Ortmann O, Schulz KD, Emmons G. Expression of luteinizing hormone-releasing hormone and its mRNA in human endometrial cancer cell lines. J Clin Endocrinol Metab 1994;79:916&#8211;919.</td><td><a href=http://dx.doi.org/10.1210/jc.79.3.916>10.1210/jc.79.3.916</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60_2</td><td>BibArticle</td><td>Harris NS, Dutlow C, Eidne K, et al. Gonadotropin-releasing hormone gene expression in MDA-MB-231 and ZR-75-1 breast carcinoma cell lines. Cancer Res 1991;51:2577&#8211;2581.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR61_2</td><td>BibArticle</td><td>Emons G, M&#252;ller V, Ortmann O, Schultz KD. Effects of LHRH analogues on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol 1998;65:199&#8211;205.</td><td><a href=http://dx.doi.org/10.1016/S0960-0760(97)00189-1>10.1016/S0960-0760(97)00189-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62_2</td><td>BibArticle</td><td>Tang X, Yano T, Osuga Y, et al. Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. J Clin Endocrinol Metab 2002;87:3721&#8211;3727.</td><td><a href=http://dx.doi.org/10.1210/jc.87.8.3721>10.1210/jc.87.8.3721</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63_2</td><td>BibArticle</td><td>Sharoni Y, Bosin E, Minster A, et al. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1989;86:1648&#8211;1651.</td><td><a href=http://dx.doi.org/10.1073/pnas.86.5.1648>10.1073/pnas.86.5.1648</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64_2</td><td>BibArticle</td><td>Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M. Antiproliferative effects of LHRH agonists on the human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine inhibitory LHRH loop. Cancer Res 1994;54:4091&#8211;4095.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR65_2</td><td>BibArticle</td><td>Hawes BE, Conn PM. Assessment of the role of G proteins and inositol phosphate production in the action of gonadotropin-releasing hormone. Clin Chem 1993;39:325&#8211;332.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR66_2</td><td>BibArticle</td><td>V&#246;lker P, Gr&#252;ndker C, Schmidt O, Schultz K-D, Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: Frequency, autoregulation, and correlation with direct antirpoliferative activity of luteinizing hormone-releasing hormone analogs. Am J Obstet Gynecol 2002;186:171&#8211;179.</td><td><a href=http://dx.doi.org/10.1067/mob.2002.119633>10.1067/mob.2002.119633</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67_2</td><td>BibArticle</td><td>Shedgley KR, Finch AR, Caunt CJ, McArdle CA. Intracellular gonadotropin-releasing hormone receptors in breast and gonadotrope lineage cells. J Endocrinol 2006;191:625&#8211;636.</td><td><a href=http://dx.doi.org/10.1677/joe.1.07067>10.1677/joe.1.07067</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68_2</td><td>BibArticle</td><td>Cheng CK, Leung PCK. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005;26:283&#8211;306.</td><td><a href=http://dx.doi.org/10.1210/er.2003-0039>10.1210/er.2003-0039</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69_2</td><td>BibArticle</td><td>Gr&#252;ndker C, Gunthert AR, Westphalen S, Emons G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002;146:1&#8211;14.</td><td><a href=http://dx.doi.org/10.1530/eje.0.1460001>10.1530/eje.0.1460001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70_2</td><td>BibArticle</td><td>Emons G, Grundker C, Gunthert AR, Westphalen S, Kavanagh J, Verschraegen C. GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003;10:291&#8211;299.</td><td><a href=http://dx.doi.org/10.1677/erc.0.0100291>10.1677/erc.0.0100291</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71_2</td><td>BibArticle</td><td>Schally AV. LH-RH analogues. I. Their impact on reproductive medicine. Gynecol Endocrinol 1999;13:401&#8211;409.</td><td><a href=http://dx.doi.org/10.3109/09513599909167587>10.3109/09513599909167587</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72_2</td><td>BibArticle</td><td>Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z. Peptide analogs in the therapy of prostate cancer. Prostate 2000;45:158&#8211;166.</td><td><a href=http://dx.doi.org/10.1002/1097-0045(20001001)45:2&lt;158::AID-PROS10&gt;3.0.CO;2-K>10.1002/1097-0045(20001001)45:2&lt;158::AID-PROS10&gt;3.0.CO;2-K</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73_2</td><td>BibArticle</td><td>Schally AV. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art. Br J Urol 2007;100(S2):2&#8211;4.</td><td><a href=http://dx.doi.org/10.1111/j.1464-410X.2007.06942.x>10.1111/j.1464-410X.2007.06942.x</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, ArticleTitle, VolumeID, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR74_2</td><td>BibArticle</td><td>Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F. Responses to the antagonistic analog of LHRH (Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 1994;24:84&#8211;92.</td><td><a href=http://dx.doi.org/10.1002/pros.2990240206>10.1002/pros.2990240206</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75_2</td><td>BibArticle</td><td>Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist Cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab1998;83:3826&#8211;3831.</td><td><a href=http://dx.doi.org/10.1210/jc.83.11.3826>10.1210/jc.83.11.3826</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR76_2</td><td>BibArticle</td><td>Debruyne F, Gress AA, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170&#8211;177.</td><td><a href=http://dx.doi.org/10.1016/j.eururo.2008.03.069>10.1016/j.eururo.2008.03.069</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77_2</td><td>BibArticle</td><td>Horvath JE, Toller GL, Schally AV, Bajo AM, Groot K. Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats. PNAS 2004;101:4996&#8211;5001.</td><td><a href=http://dx.doi.org/10.1073/pnas.0400605101>10.1073/pnas.0400605101</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78_2</td><td>BibArticle</td><td>Nagy A, Schally AV. Targeting of cytotoxic LHRH analogs to breast, ovarian, endometrial and prostate cancers. Biol Reprod 2005;73:851&#8211;859.</td><td><a href=http://dx.doi.org/10.1095/biolreprod.105.043489>10.1095/biolreprod.105.043489</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79_2</td><td>BibArticle</td><td>Nagy A, Schally AV. Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: A &#8220;smarter&#8221; chemotherapy. Curr Pharm Des 2004;14:1167&#8211;1180.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.2174/1381612053507594>10.2174/1381612053507594</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, FirstPage, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR80_2</td><td>BibArticle</td><td>Nagy A, Schally AV, Armatis P, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996;93:7269&#8211;7273.</td><td><a href=http://dx.doi.org/10.1073/pnas.93.14.7269>10.1073/pnas.93.14.7269</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81_2</td><td>BibArticle</td><td>Eaveri R, Ben-Yehudah A, Lorberboum-Galski H. Surface antigens/receptors for targeted cancer treatment: the GnRH receptor/binding site for targeted adenocarcinoma therapy. Curr Cancer Drug Targets 2004;4:673&#8211;687.</td><td><a href=http://dx.doi.org/10.2174/1568009043332745>10.2174/1568009043332745</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82_2</td><td>BibArticle</td><td>Wang X, Krebs LJ, Al-Nuri M, et al. A chemically labeled cytotoxic agent: Two-photon fluorophore for optical tracking of cellular pathway in chemotherapy. Proc Natl Acad Sci USA 1999;96:11081&#8211;11084.</td><td><a href=http://dx.doi.org/10.1073/pnas.96.20.11081>10.1073/pnas.96.20.11081</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR83_2</td><td>BibArticle</td><td>Gunthert AR, Grundker C, Bongertz T, Schlott T, Nagy A, Schally AV. Internalization of cytotoxic luteinizing hormone-releasing hormone analog AN-152 induces multi drug resistance 1 (MDR-1) independent apoptosis in human endometrial and ovarian cancer cell lines. Am J Obstet Gynecol 2004:191:1164&#8211;1172.</td><td><a href=http://dx.doi.org/10.1016/j.ajog.2004.04.020>10.1016/j.ajog.2004.04.020</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR84_2</td><td>BibArticle</td><td>Peeling WB. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 1989;33(S):45&#8211;52.</td><td><a href=http://dx.doi.org/10.1016/0090-4295(89)90106-4>10.1016/0090-4295(89)90106-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR85_2</td><td>BibArticle</td><td>Redding TW, Schally AV. Inhibition of prostate tumour growth in two rat models by chronic administration of D-Trp<Superscript>6</Superscript>-LH-RH. Proc Natl Acad Sci USA 1981;78:6509&#8211;6512.</td><td><a href=http://dx.doi.org/10.1073/pnas.78.10.6509>10.1073/pnas.78.10.6509</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86_2</td><td>BibArticle</td><td>Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing agonists. Proc Natl Acad Sci USA 1982;79:1658&#8211;1662.</td><td><a href=http://dx.doi.org/10.1073/pnas.79.5.1658>10.1073/pnas.79.5.1658</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87_2</td><td>BibArticle</td><td>Sogani PC, Fair WR. Treatment of advanced prostate cancer. Urol Clin North Am 1987;14:253&#8211;271.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR88_2</td><td>BibArticle</td><td>Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419&#8211;424.</td><td><a href=http://dx.doi.org/10.1056/NEJM198908173210702>10.1056/NEJM198908173210702</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR89_2</td><td>BibChapter</td><td>Gonzalez-Barcena D, Schally AV, Comaru-Schally AM, Cortez-Morales A, Vadillo-Buenfil M, Molina-Ayala MA. Treatment of patients with advanced prostate cancer with LH-RH antagonist Cetrorelix. In: Filicori M, Flamigni C, eds. Treatment with GnRH analogs: Controversies &amp; perspectives, London/New York: Parthenon, 1996;139&#8211;144.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR90_2</td><td>BibArticle</td><td>Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, et al. Luteinizing hormone-releasing hormone antagonist SB-75 (Cetrorelix) as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology 1995;45:275&#8211;281.</td><td><a href=http://dx.doi.org/10.1016/0090-4295(95)80018-2>10.1016/0090-4295(95)80018-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91_2</td><td>BibArticle</td><td>Trachtenberg J, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002;167:1670&#8211;1674.</td><td><a href=http://dx.doi.org/10.1097/00005392-200204000-00021>10.1097/00005392-200204000-00021</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92_2</td><td>BibArticle</td><td>Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix study group. Mol Urol 2000;4:275&#8211;277.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR93_2</td><td>BibArticle</td><td>Beer TM, Ryan C, Bhat G, Garnick M, Abarelix Study Group. Dose-escalated abarelix in androgen-independent prostate cancer: A phase I study. Anti-Cancer Drugs 2006;17:1075&#8211;1079.</td><td><a href=http://dx.doi.org/10.1097/01.cad.0000231476.84782.55>10.1097/01.cad.0000231476.84782.55</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94_2</td><td>BibArticle</td><td>Schally AV, Varga JL, Engel JB. Drug Insight: Antagonistic growth hormone-releasing hormone: An emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008;4:33&#8211;43.</td><td><a href=http://dx.doi.org/10.1038/ncpendmet0677>10.1038/ncpendmet0677</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR95_2</td><td>BibArticle</td><td>Stangelberger A, Schally AV, Zarandi M, et al. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-Pca-2b and LuCaP-35 prostate cancers. Prostate 2007;67:1339&#8211;1353.</td><td><a href=http://dx.doi.org/10.1002/pros.20605>10.1002/pros.20605</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96_2</td><td>BibArticle</td><td>Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 2003;9:4505&#8211;4513.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR97_2</td><td>BibArticle</td><td>Plonowski A, Schally AV, Nagy A, et al. Inhibition of in vivo proliferation of MDA-Pca-2b human prostate cancer by targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Cancer Lett 2002;176:57&#8211;63.</td><td><a href=http://dx.doi.org/10.1016/S0304-3835(01)00734-0>10.1016/S0304-3835(01)00734-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR98_2</td><td>BibArticle</td><td>Kov&#225;cs M, Schally AV, Nagy A, Kopp&#225;n M, Groot K. Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1997;94:1420&#8211;1425.</td><td><a href=http://dx.doi.org/10.1073/pnas.94.4.1420>10.1073/pnas.94.4.1420</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR99_2</td><td>BibArticle</td><td>Kov&#225;cs M, Schally AV, Csernus B, Busto R, R&#233;k&#225;si Z, Nagy A. Targeted cytotoxic analogue of luteinizing hormone-releasing hormone (LH-RH) only transiently decreases the gene expression of pituitary receptors for LH-RH. J Neuroendocrinol 2002;14:5&#8211;13.</td><td><a href=http://dx.doi.org/10.1046/j.0007-1331.2001.00728.x>10.1046/j.0007-1331.2001.00728.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR100_2</td><td>BibArticle</td><td>Emons G, Kauffmann M, Gunthert AR, et al. Phase I study of Zen-008 (AN-152), a targeted cytotoxic LHRH analog in female patients with cancers expressing LHRH receptors. J Clin Oncol, ASCO Annual Meeting Proceedings 2007;25(18S):3571.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></table>